Karolinska University Hospital, Dept. of Anesthesia and Intensive Care, Sweden
Stockholm, Huddinge, SE-141 86, Sweden
NCT Number: NCT02811380
The primary objective of this trial was to determine Bactiguard coated BIP CVC's safety and performance and compare it to corresponding standard uncoated CVC.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Stockholm, Huddinge, SE-141 86, Sweden
The primary objective of this study is to determine the safety for the medical device of 'BIP central venous catheter". Safety is assessed by evaluation of adverse events (according to ISO 14155:2011). Examples of CVC related common events are phlebitis, infection at the infection site, catheter related bacteremia/fungemia, septicemia, sepsis, thrombosis, lung emboli and pneumothorax.
The secondary objective is to assess the overall performance by evaluating if there were any CVC handling problems experienced by the physician/health care personnel.
Furthermore, an exploratory objective of this study is to assess coating and microbial colonization.
Included in the study were men and women aged 18 years or older undergoing elective standardized large surgery with a planned CVC catheterization in right or left jugular vein or subclavian vein planned for at least 3 days.
This study is a single-centre, randomized, single-blind, controlled study of tolerability and safety of BIP CVC with noble metal alloy coating.
All statistical analyses is performed using the SAS® System, version 9.3 or higher (SAS Institute Inc., Cary, NC, USA). Data is to be summarized using descriptive statistics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
Other names: BIP Central Venous Catheter, Bactiguard coated CVC, Noble metal alloy coated Central Venous Catheter
Standard CVC catheterization for venous access during and after elective large surgery
Other names: Standard CVC, Standard Central Venous Catheter, Uncoated CVC, Uncoated Central Venous Catheter
Time frame: Through study completion, an average of 10 days
Overall assessment of safety by evaluation of CVC related adverse events and any problems in post operative course.
Time frame: Through study completion, an average of 10 days
Overall assessment of device performance by evaluation of any CVC handling problems experienced by the physician/health care personnel.
Bactiguard AB
Industry
Evaluation of Safety and Performance of the BIP Central Venous Catheter With Anti-infective Coating
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05320718
Anesthesia, Local, Regional Anesthesia
Beijing, Beijing Municipality, China
View Trial DetailsNCT05552092
Surgery
Gwangju, South Korea
View Trial DetailsNCT03369210
Anemia, Hematologic Diseases
Aachen, Germany
View Trial DetailsNCT04846855
Anesthesia, Local, Hematologic Diseases
Quincy-sous-Sénart, IDF, France
View Trial Details